According to a recent LinkedIn post from Resolution Therapeutics, company representatives attended the ISCT 2026 meeting in Dublin and highlighted several trends they perceive in the cell and gene therapy (CGT) landscape. The post points to a shift beyond traditional CAR-T and rare disease gene therapy toward regenerative medicine indications such as liver disease and Type I diabetes, with macrophages, mesenchymal stem cells (MSCs), and MSC-derived extracellular vesicles featuring prominently in scientific discussions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post also emphasizes what it describes as a strong culture of collaboration within the CGT community and growing efforts to “democratise” access to advanced therapies. It references perceived momentum among sponsors, regulators, payers, and standardization bodies toward harmonized requirements across geographies, which, if realized, could support broader patient access and potentially smoother global development and commercialization pathways.
Another theme in the post is the role of artificial intelligence in therapy discovery and development. While the post suggests that meaningful benefits in GMP manufacturing may still be some distance away, it indicates that the direction of progress is clear, implying a future potential for efficiency gains and cost improvements across the CGT value chain, which investors may view as relevant to scalability and margins.
The LinkedIn post situates Resolution Therapeutics’ lead program, RTX001, within this perceived industry inflection point, describing it as a regenerative, immunomodulatory therapy targeting unmet need in end-stage liver disease. For investors, this framing suggests that the company views its pipeline as aligned with evolving scientific and regulatory priorities in CGT, potentially positioning it to benefit if regenerative cell therapies gain greater clinical validation, reimbursement support, and international regulatory harmonization.